On 2/29/24, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) stock suffered a major decline of -37.6%, closing at $9.43. Moreover, trading volume in this decline was exceptionally high at 835% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -37.7% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, IRWD is expected to be a major Value Eraser.
Ironwood Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment